Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein

Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. In a phase 1b 3-day monotherapy study, patients treated with a 150-mg dose of GS-5816 had a mean maximal HCV RNA decline...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Antimicrob Agents Chemother
Главные авторы: Lawitz, Eric J., Dvory-Sobol, Hadas, Doehle, Brian P., Worth, Angela S., McNally, John, Brainard, Diana M., Link, John O., Miller, Michael D., Mo, Hongmei
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology 2016
Предметы:
Antiviral Agents
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4997818/
https://ncbi.nlm.nih.gov/pubmed/27353271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00763-16
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы